Россииское кардиологическое общество Российское научное медицинское общество терапевтов Антигипертензивная лига
 Скачать 3.62 Mb.
|
|
234. Lancefield T, Clark DJ, Andrianopoulos N et al. Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. JACC Cardiovasc Interv 2010;3:660-8. 235. Nikolsky E, Kosinski E, Mishkel GJ et al. Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial). Am J Cardiol 2005; 95:709-15. 236. Anfossi G, Russo I, Trovati M. Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 2009;19:440-9. 237. Badimon L, Hernandez VR, Padro T, Vilahur G. Antithrombotic therapy in obesity. Thromb Haemost 2013; 110:681-8. 238. Pankert M, Quilici J, Loundou AD et al. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting. Am J Cardiol 2014; 113:54-9. 239. Storey RF, Becker RC, Harrington RA et al. Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. Eur Heart J 2011;32: 2945-53. 240. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361: 1045-57. 241. Pullan M, Kirmani BH, Conley T et al. Should obese patients undergo on- or off-pump coronary artery bypass grafting? Eur J Cardiothorac Surg 2015; 47:309-15. 242. Wagner BD, Grunwald GK, Rumsfeld JS, et al. Relationship of body mass index with outcomes after coronary artery bypass graft surgery. Ann Thorac Surg 2007; 84:10-6. 243. Benedetto U, Danese C, Codispoti M. Obesity paradox in coronary artery bypass grafting: myth or reality? J Thorac Cardiovasc Surg 2014;147:1517-23. 244. Totaro P. Obesity and coronary surgery: new concepts for an old problem. ExpertRevCardiovascTher 2008; 6:897-903.36 245. Alam M, Siddiqui S, Lee VV et al. Isolated coronary artery bypass grafting in obese individuals: a propensity matched analysis of outcomes. Circ J 2011;75:1378-85. 246. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-13. 247. Alpert MA, Terry BE, Mulekar M et al. Cardiac morphology and left ventricular function in morbidly obese patients with and without congestive heart failure and effect of weight loss. Am J Cardiol 1997; 80:736-740. 248. Levitan EB, Yang AZ, Wolk A, Mittleman MA. Adiposity and incidence of heart failure hospitalization and mortality: a population-based prospective study. Circ Heart Fail 2009;2:202-8. 249. Schmidt M, Bøtker HE, Pedersen L, Sørensen HT. Young adulthood obesity and risk of acute coronary syndromes, stable angina pectoris, and congestive heart failure: a 36-year cohort study. Ann Epidemiol 2014; 25: 356-61. 250. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA 1991;266:231-6. 148 251. Alpert MA, Omran J, Mehra A, Ardhanari S. Impact of obesity and weight loss on cardiac performance and morphology in adults. Prog Cardiovasc Disc 2014;56:391-400. 252. Lavie CJ, Alpert MA, Arena R, Mehra MR, Milani RV, Ventura HO. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. J Am Coll Cardiol HF 2013;1:93-102. 253. Clark AL, Fonarow GC, Horwich TB. Obesity and obesity paradox in heart failure. Prog Cardiovasc Dis 2014; 56:409-414. 254. Pascual M, Pascual DA, Soria F et al. Effects of isolated obesity on systolic and diastolic ventricular function. Heart 2003 ;89: 1152-1156. 255. Sarzani R, Dessí-Fulgheri P, Paci VM, Espinosa E, Rappelli A. Expression of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol Invest 1996;19:581-5. 256. Sengenes C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J 2000;14:1345-51. 257. Kenchaiah S, Pocock SJ, Wang D et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007;116:627-36. 258. Horwich TB, Broderick S, Chen L et al. Relation among body mass index, exercise training, and outcomes in chronic systolic heart failure. Am J Cardiol 2011;108:1754-9. 259. Kapoor JR, Heidenreich PA. Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship. Am Heart J 2010;159:75-80. 260. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The Relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 2001;38:789-95. 261. Fonarow GC, Srikanthan P, Costanzo MR, Cintron GB, Lopatin M, ADHERE Scientific Advisory Committee and Investigators. An obesity paradox in acute heart failure: analysis of body mass index and in-hospital mortality for 108,927 patients in the Acute Decompensated Heart Failure National Registry. Am Heart J 2007;153:74-81. 262. Sharma A, Lavie CJ, Borer JS,et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol 2015;115:1428-1434. 263. Shah R, Gayat E, Januzzi JL et al. Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. J Am Coll Cardiol 2014;63:778-785. 264. Zamora E, Lupón J, de Antonio M, et al. The obesity paradox in heart failure: is etiology a key factor? Int J Cardiol 2013;166:601-5. 265. The European Agency for the Evaluation of Medicinal Products. EMEA public statement on recent publications regarding hormone replacement therapy; 2003. 266. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA. 2004;291:1701-1712. 267. Cook NR, Buring JE, Ridker PM. The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 2006;145:21-29. 149 268. Hodis HN, Mack WJ, Shoupe D, et al. Testing the menopausal hormone therapy timing hypothesis: the Early Vs Late Intervention Trial with Estradiol. Circulation. 2014;130:A13283. 269. Steinkellner AR, Denison SE, Eldridge SL, Lenzi LL, Chen W, Bowlin SJ. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative.Menopause 2012;19:616-621. 270. The study is the ELITE trial, the Early Vs Late Intervention Trial with Estradiol 271. Fauser BC, Tarlatzis BC, Rebar RW et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM- Sponsored 3rd PCOS Consensus Workshop Group // Fertil. Steril. 2012. Vol. 97. № 1. P. 28–38. 272. Morgan CL, Jenkins-Jones S, Currie CJ et al. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study // J. Clin. Endocrinol. Metab. 2012. Vol. 97. № 9. P. 3251–3260. 273. Moran LJ, Misso ML, Wild RA et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis // Hum. Reprod. Update. 2010. Vol. 16. № 4. P. 347– 363. 274. Калинченко С. Ю., Роживанов Р. В. Особенности лечения мужчин с ожирением. Ожирение и метаболизм 2005;3:39–42. 275. Svartberg J et al Waist circumference and testosterone levels in community dwelling men. The Tromsш study. Europ J Epidemiol 2004;19(7):657–63 276. Saad F. The role of testosterone in type 2 diabetes and metabolic syndrome in men. ArqBrasEndocrinolMetabol, vol. 53, no. 8, p. 901–907, 2009. 277. Stanworthand RD, Jones TH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Frontiers of Hormone Research, vol. 37, p. 74–90, 2009. 278. Traish M, Saad F, Guay A. The darkside of testosterone deficiency: II. type 2 diabetes and insulinresistance // Journal of Andrology. 2009.Vol. 30. № 1. P. 23–32. 279. Андрология. Мужское здоровье и дисфункция репродуктивной системы: под ред. Э. Нишлага, Г. М. Бере. М., 2005. 554 с. 280. Leenen R, van der Kooy K, Seidell JC et al. Visceral fat accumulation in relation to sex hormones in obese men and women undergoing weight loss therapy. J. Clin. EndocrinolMetab 1994;78:1515–1520 281. Kaufman JM, Vermeulen A. The decline of androgen level sin elderly men and its clinical and therapeutic implications. EndocrineReviews, vol. 26, no. 6, p. 833–876, 2005 (59). 282. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome // The Lancet. 2005.Vol. 365, № 9468. Р. 1415–1428. 283. Lima N, Cavaliere H, Knobel M, Halpern A, and Medeiros-Neto G. Decreased androgen levels in massively obese men may be associated with impaired function of the gonadostat // International Journal of Obesity. 2000. Vol. 24. № 11. Р. 1433–1437. 284. Stamler J, Stamler R, Riedlinger WF, Algera G, Roberts RH. Hypertension screening of 1 million Americans. Community Hypertension Evaluation Clinic (CHEC) program, 1973 through 1975. JAMA, vol. 235, no. 21. P. 2299– 2306, 1976. 150 285. Isidori M, Caprio M, Strollo F et al. Leptin and androgen sin male obesity: evidence for leptin contribution to reduced androgen levels // Journal of Clinical Endocrinology and Metabolism. 1999. Vol. 84. № 10. P.3673–3680. 286. Goncharov NP, Katsya GV, Chagina NA, Gooren LJ. Testosterone and obesity in men under the age of 40 years // Andrologia. 2009. Vol. 41. № 2. P. 76–83. 287. Дедов И. И., Калинченко С. Ю. Возрастной андрогенный дефицит у мужчин. М.: Практическая медицина, 2006. 288. Cunningham GR. Management of male aging: which testosterone replacement therapy should be used? The Aging Male 2000;3:203–209, 289. Yassin A, Saad F. Long-Acting Testosterone Ester injection as a First Line Therapy in hypogonadal patients with Erectile Dysfunction. Int. J. Androl 2005;28(Suppl.1):53 290. Vermeulen A. Androgen sin the aging male // JClinEndocrinolMctab 1991;73:221-4. 291. Гамидов С. И., Овчинников Р. И., Павловичев А. А. и др. Эффективность и безопасность препаратов тестостерона в лечении андрогенного дефицита у мужчин // Фарматека. 2009. № 16. С. 23–30. 292. Роживанов Р. В., Курбатов Д. Г. Особенности терапии эректильной дисфункции у пациентов с андрогенным дефицитом // Врач. 2009. № 3. С. 1– 4. 293. Верткин А. Л., Моргунов Л. Ю., Наумов А. В. и др. Эффективность заместительной гормональной терапии тестостероном ундеканоатом в клиническом лечении мужчин с соматической патологией // Фарматека. 2008. № 9. С. 1–5. 294. Isaacs JT. Testosterone and prostate / Nieschlag E, Behre HM (eds.) // Testosterone: action, deficiency, substitution 3 rd ed. Cambridge University Press. 2004. 347-74.16. 295. Schatzl G, Reiter WJ., Thurridl T et al. Endocrine patterns in patients with benign and malignant prostatic diseases // Prostate. 2000. 44: 219-24. 17. 296. Пушкарь Д. Ю., Сегал А. С. Андрогенозаместительная терапия и состояние предстательной железы // Фарматека. 2006. № 15. С. 62–65. 297. Hsing AW. Hormones and prostate cancer: what's next? Epidemiol // Rev. 2001; 23:42-58. 21. 298. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring // New England J. of Med. 2004; 350: 482-92. 299. Finley MR, Curruthers ME. Androgens, the prostate and safety of testosterone treatment. The Aging Male 2006; 9(1):4. 300. Вёрткин А. Л., Моргунов Л. Ю. Оценка безопасности и эффективности небидо у мужчин с андрогенным дефицитом: сравнительный зарубежный и отечественный опыт // Врач скорой помощи. 2013. № 2. С. 047–054. 301. Effects of Testosterone Undecanoate on Cardiovascular Risk Factors and Atherosclerosis in Middle-Aged Men with Late-Onset Hypogonadism and Metabolic Syndrome: Results from a 24-month, Randomized, Double-Blind, Placebo-Controlled Study. Aversa A, Bruzziches R, et al. J Sex Med. 2010 Jul 14. (Epub ahead of print) 302. Esposito К, Giugliano D Obesity, the metabolic syndrome, and sexual dysfunction. IntJImpotRes 2005; 17: 391–8. 303. Аметов А. С., Стельмах М. В. Эректильная дисфункция и ожирение // Тер. архив. 2013. № 10. С. 88–93. 151 304. Калинченко С. Ю. Ожирение и нарушения репродуктивной функции у мужчин // Ожирение / под ред. И. И.Дедова, Г . А. Мельниченко. М., 2004. 305. Esposito K, Giugliano F, DiPalo C et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291 (24): 2978–84. 306. Иремашвили В. В. Новый подход к лечению больных эректильной дисфункцией: постоянный прием ингибиторов фосфодиэстеразы 5 типа // Русский медицинский журнал. 2008. Т. 16. С. 620-4. 307. Parati G, Lombardi C, Hedner J, Bonsignore MR, GroteL, Tkacova R et al. Position paper on the management of patients with obstructive sleep apnea and hypertension: joint recommendations by the European Society of Hypertension, by the European Respiratory Society and by the members of European COST (Co-operation in Scientific and Technological research) ACTION B26 on obstructive sleep apnea. JHypertens 2012; 30:633–646. 308. Obstructive Sleep Apnea Syndrome (780.53-0). The International Classification of Sleep Disorders. American Academy of Sleep Medicine. 2010. pp. 52–8. 309. de Jonge L, Zhao X, Mattingly MS, Zuber SM, Piaggi P, Csako G, Cizza G; NIDDK Sleep Extension Study Group. Poor sleep quality and sleep apnea are associated with higher resting energy expenditure in obese individuals with short sleep duration. // J Clin Endocrinol Metab. 2012 Aug;97(8):2881-9. 310. Brochu-Gaudreau, K., Rehfeldt, C., Blouin, R., Bordignon, V., Murphy, B. D., Palin, M. F. Adiponectin action from head to toe. // Endocrine. 2010 Feb;37(1):11-32. 311. Carnagarin, R., Dharmarajan, A. M., Dass, C. R. PEDF-induced alteration of metabolism leading to insulin resistance. // Mol Cell Endocrinol. 2015 Feb 5; 401:98-104. 312. Punjabi NM, Shahar E, Redline S, Gottlieb DJ, Givelber R, Resnick HE; Sleep Heart Health Study Investigators. Sleep-disordered breathing, glucose intolerance, and insulin resistance: the Sleep Heart Health Study. // Am J Epidemiol. 2004 Sep 15;160(6):521-30. 313. Araújo Lda S, Fernandes JF, Klein MR, Sanjuliani AF. Obstructive sleep apnea is independently associated with inflammation and insulin resistance, but not with blood pressure, plasma catecholamines, and endothelial function in obese subjects. // Nutrition. 2015 Nov-Dec;31(11-12):1351-7. 314. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardio metabolic risk in obesity and the metabolic syndrome. // J Am Coll Cardiol. 2013 Aug 13;62(7):569-76. 315. Reutrakul S, Van Cauter E. Interactions between sleep, circadian function, and glucose metabolism: implications for risk and severity of diabetes. // Ann N Y Acad Sci. 2014 Apr; 1311:151-73. 316. Stamatakis K.A., Punjabi N.M. Effects of sleep fragmentation on glucose metabolism in normal subjects. // Chest. 2010 Jan;137(1):95-101. 317. Campos-Rodriguez F., Grilo-Reina A., Perez-Ronchel J. et al. Effect of continuous positive airway pressure on ambulatory BP in patients with sleep apnea and hypertension: a placebo-controlled trial. // Chest 2006; 129:1459-67. 318. Coughlin S.R., Mawdsley L., Mugarza J.A. et al. Cardiovascular and metabolic effects of CPAP in obese males with OSA. // Eur Respir J 2007; 29: 720-7. 319. Durán-Cantolla J., Aizpuru F., Montserrat J.M. et al. Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial. // BMJ 2010; 341: c 5991. 152 320. Lozano L., Tovar J.L., Sampol G. et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. // J Hypertens 2010; 28:2161-8. 321. Harsch I.A., Schahin S.P., Redespiel-Tröger M. et al. Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnoea syndrome. // Am J Respir Crit Care Med 2004; 69:156- 62. 322. Dorkova Z., Petrasova D., Molcanyiova A. et al. Effects of continuous positive airway pressure on cardiovascular risk profile in patients with severe obstructive sleep apnoea and metabolic syndrome. // Chest 2008; 134:686-92. 323. Robinson G.V., Pepperell J.C., Segal H.C. et al. Circulating cardiovascular risk factors in obstructive sleep apnoea: data from randomised controlled trials. // Thorax 2004; 59:777-82. 324. Börgel J., Sanner B.M., Bittlinsky A. et al. Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels. // Eur Respir J 2006; 27:121-7. 325. Steiropoulos P., Tsara V., Nena E. et al. Effect of continuous positive airway pressure treatment on serum cardiovascular risk factors in patients with obstructive sleep apnea-hypopnea syndrome. // Chest 2007; 132:843-51. 326. Lazarus R, Sparrow D, Weiss ST. Effects of obesity and fat distribution on ventilatory function: the normative aging study. Chest 1997;111:891-8. 327. Chinn DJ, Cotes JE, Reed JW. Longitudinal effects of change in body mass on measurements of ventilatory capacity. Thorax 1996;51:699-704. 328. Rubinstein I, Zamel N, DuBarry L et al. Airflow limitation in morbidly obese, nonsmoking men. Ann Intern Med 1990;112:828-32 329. |